Home LifestyleHealth The Israeli Prime Minister claims to be the first to be vaccinated against Pfizer Coronavirus
The Israeli Prime Minister claims to be the first to be vaccinated against Pfizer Coronavirus

The Israeli Prime Minister claims to be the first to be vaccinated against Pfizer Coronavirus

by YCPress

December 10 TodayRussian TV reported on the 10th that Israeli Prime Minister Netanyahu announced on the 9th that he would voluntarily become the first Israeli to be vaccinated against Pfizer against the novel coronavirus.

He also said that the government will soon be able to provide 60,000 vaccines a day to the people, and everyone is welcome to vaccinate.

On the 9th, local time, Netanyahu held a press conference after meeting with the Israeli health minister. At the press conference, he announced that he would be the first person in Israel to be vaccinated against the novel coronavirus.

He also said that Israel’s health department is ready to provide 60,000 vaccines to the public every day.

Netanyahu called on “every Israeli” to be vaccinated and said that the government is studying a “green pass” plan.

According to the plan, vaccinated people can experience various facilities and services by presenting a card or an application and freely accessing public places such as shopping malls.

It is reported that the first batch of vaccines jointly developed by Pfizer Pharmaceuticals and German partner BioNTech have arrived in Israel earlier on the 9th, and a “significant” of vaccines will arrive in the country soon.

However, the day before, two NHS health workers with a history of severe allergy developed symptoms similar to allergic reactions after being vaccinated against Pfizer on the 8th.

The U.S. Food and Drug Administration said recently that four volunteers receiving the third phase of Pfizer vaccine developed Bell’s paralysis, that is, facial paralysis.

British regulators responded on the 9th that people with a history of “serious” allergies should not be vaccinated against Pfizer at present.

In critical phase III clinical trials, the vaccine is generally well tolerated, and the Independent Data Monitoring Board also reports that there are no serious safety problems.